Johnson & Johnson’s Cash Flow Jumped, but Margins Slipped

Johnson & Johnson’s Q2 FY2026 result improved meaningfully on revenue and cash generation but was less convincing on per-share earnings and operating profitability. Revenue reached $25.31 billion, up from $23.74 billion in Q2 FY2025. That is an increase of $1.57 billion, or 6.6%, and it also marked an acceleration from the $24.06 billion reported in Q1 FY2026. With no company guidance or consensus estimate supplied, the year-earlier quarter is the appropriate comparison under our methodology.

Gross margin increased to 68.2% from 67.9% a year earlier, a 0.3-percentage-point improvement. Gross profit was $17.26 billion. The movement is directionally positive because the company retained slightly more of each revenue dollar after the costs captured above gross profit. It also reversed part of the pressure seen in Q1 FY2026, when gross margin was 66.3%, according to the quarterly figures associated with the Johnson & Johnson Q2 FY2026 Form 10-Q.

The improvement stopped before the operating-income line. Operating margin was 26.7%, compared with 27.3% in Q2 FY2025. Operating income totaled $6.75 billion. EPS declined to $2.27 from $2.29, despite the higher revenue and gross margin. The supplied filing extract does not provide enough expense detail to identify which operating-cost categories caused the margin decline, so attributing it to research, selling costs, litigation or another item would go beyond the evidence.

Free cash flow was the quarter’s clearest positive. Cash from operations totaled $11.13 billion and capital expenditure was $2.37 billion, producing the supplied free-cash-flow figure of $7.29 billion. That compares with $2.83 billion in Q2 FY2025 and $1.47 billion in Q1 FY2026. Quarterly cash flow can be affected by working-capital timing, but the size of the year-over-year improvement is nevertheless material. Net debt was $16.92 billion, up from $15.84 billion in the preceding quarter but below the $21.73 billion recorded at FY2025 year-end.

The quarter supports one part of the quality thesis while challenging another. Revenue growth of 6.6% and improved gross margin indicate that the business expanded without sacrificing product-level profitability. Free cash flow also converted strongly: $7.29 billion in one quarter represents roughly one-third of the supplied $22.2 billion trailing total. Those figures strengthen confidence that reported earnings are accompanied by cash generation, although one quarter should not be annualized mechanically.

The challenge is that revenue growth did not produce operating leverage. Operating margin declined 0.6 percentage points year over year, and EPS fell by $0.02. A company trading at 30.9x trailing EPS generally needs either durable earnings growth, improving returns or unusually low business risk to sustain that valuation. Q2 delivered stronger sales and cash flow, but it did not deliver broad-based improvement across the income statement.

The longer-period figures remain respectable. FY2025 revenue increased 6.0% to $94.19 billion, operating margin was 34.6% and ROIC was 20.9%. However, the quarterly operating margin of 26.7% was materially below that annual figure. Comparability may be affected by timing or items not described in the supplied extract, but the gap reinforces the need to distinguish between recurring operating performance and period-specific effects. The absence of an earnings release also means there is no supplied management explanation or updated outlook to resolve that question.

The thesis therefore changes only modestly after the quarter. Cash generation is better than the EPS result alone suggests, and gross margin moved in the right direction. Yet the lower operating margin prevents the revenue beat from becoming an unambiguously bullish signal. This is a mixed operating update rather than evidence of a new earnings trajectory.

With no prior SageNoodle coverage, this article initiates rather than revises fair value. Our base case is $216 per share, calculated by applying an assumed 25x multiple to supplied trailing EPS of $8.62 and rounding the resulting $215.50. The multiple is an analyst assumption, not company guidance. It recognizes Johnson & Johnson’s 20.9% FY2025 ROIC, 6.0% FY2025 revenue growth and substantial free-cash-flow production, while allowing for the mixed Q2 margin and EPS performance.

The bear case is $155 per share. It applies an assumed 18x multiple to trailing EPS of $8.62, producing approximately $155. This case would become more relevant if the Q2 operating-margin decline persists, EPS fails to grow despite higher revenue, or cash conversion falls back toward weaker quarterly levels. We assign it a 25% probability.

The base case receives a 50% probability and assumes that revenue continues to grow at a moderate rate, free cash flow remains healthy across a full year, and operating profitability stabilizes rather than deteriorates. The bull case is $267 per share, based on an assumed 31x trailing P/E and assigned a 25% probability. It requires the market to continue awarding a premium multiple while the company converts revenue growth into renewed EPS and operating-margin improvement. At $267, the bull case is effectively aligned with the current price of $266.35.

At the current quotation, the stock trades at 30.9x trailing EPS and offers a 3.4% trailing free-cash-flow yield. Our $216 base value is 18.9% below the market price, meeting the stated threshold for an Overvalued verdict. The scenario-weighted value is approximately $214 per share, close to the base case. EV/EBITDA was not disclosed in the supplied data; the snapshot records zero solely as a not-available placeholder, not as a valuation observation. Q2 improved the evidence behind cash generation, but not enough to warrant valuing the whole company near the bull-case multiple.

The bearish valuation conclusion could prove too conservative if Q2’s cash-flow improvement represents a durable change rather than timing. If free cash flow remains near the stronger quarterly run rate while revenue continues growing around the recent pace, a premium multiple could be defensible even without immediate operating-margin expansion. The bull case would also gain credibility if later filings show that the Q2 EPS and operating-margin declines reflected temporary or nonrecurring costs.

The opposite risk is that the quarter’s free cash flow overstates sustainable conversion. Cash flow moved from $1.47 billion in Q1 to $7.29 billion in Q2, illustrating how sharply quarterly working-capital movements can affect the result. Without detailed cash-flow commentary in the supplied materials, the durability of the increase cannot be established from this quarter alone. A reversal would remove the strongest positive feature of the print.

Persistent operating deleverage is the central fundamental risk. Revenue rose by $1.57 billion year over year, but operating margin and EPS both declined. If that pattern continues, it would indicate that incremental revenue carries insufficient operating profit or that expenses are rising faster than gross profit. Either outcome would weaken the case for applying a 25x base multiple.

Valuation itself is the final risk. The current price already corresponds closely to our 31x bull-case multiple. Results therefore need to become more consistently positive across revenue, margins, EPS and cash flow. Q2 satisfied two of those four tests convincingly, but not all four. The next filing must show whether the margin weakness was temporary and whether the cash-flow gain can be repeated.